New evidence
Crocin cut heart-function decline during chemo from 17.7% to 7.2% in a 6-month trial — but only in breast cancer patients on a specific drug regimen.
This is the first solid randomized evidence that crocin, a compound from gardenia, might protect the heart during anthracycline chemotherapy, but it’s a single early study in a very specific clinical population — so the finding needs replication before you can trust it for anyone else.
The study followed 200 breast cancer patients receiving anthracycline-based chemotherapy, a regimen known to sometimes damage the heart. Those who took crocin tablets had a significantly lower rate of decline in their heart’s pumping ability (left ventricular ejection fraction) — 7.2% versus 17.7% in the placebo group. While promising, the results come from a small, single trial with an unspecified dose, so the protective effect may not apply to other people or situations.
Where this fits in the evidence
This is among the first studies we've indexed on Gardenia for Reduced Decline in Left Ventricular Ejection Fraction — treat it as an early signal until more research accumulates.
The study
- Randomized Controlled Trial (RCT)
- n = 200
- 2025-03
- Pharmacological research
This is a plain-language summary of a research finding, not medical advice. Pillser surfaces research signals to help you decide what's worth investigating — always consult a qualified professional before changing what you take.